Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Monoclonal Antibody for Patients with Covid-19. Reply

    Publikation: Bidrag til tidsskriftLetterpeer review

  4. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cardiovascular comorbidities as predictors for severe COVID-19 infection or death

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association between the E-wave propagation index and left ventricular thrombus formation after ST-elevation myocardial infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Right atrial strain: Tapping into a new reservoir of hemodynamic information

    Publikation: Bidrag til tidsskriftLederpeer review

  4. Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Left Atrial Strain Predicts Heart Failure and Cardiovascular Death in Patients Undergoing Coronary Artery Bypass Grafting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • GALACTIC-HF Investigators
Vis graf over relationer

BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.

METHODS: We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes.

RESULTS: During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups.

CONCLUSIONS: Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind384
Udgave nummer2
Sider (fra-til)105-116
Antal sider12
ISSN0028-4793
DOI
StatusUdgivet - 14 jan. 2021

Bibliografisk note

Copyright © 2020 Massachusetts Medical Society.

ID: 61894279